Companies › Xenon Pharmaceuticals
2 active drug programs in 8 registered trials: 7 Phase 3, 1 Phase 2; Psychiatry, Neurology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Azetukalner hERG potassium channel blocker | Ion channels | Phase 3 | Major Depressive Disorder; Bipolar Disorder; Bipolar Depression | Dec 2026 |
| XEN1101 Kv7 channel opener | Ion channels | Phase 3 | Primary Generalized Tonic-Clonic Seizures; Focal Onset Seizures; Focal Epilepsy | Apr 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06775379 | Azetukalner | Phase 3 | Major Depressive Disorder | Psychiatry | Dec 2026 |
| NCT06922110 | Azetukalner | Phase 3 | Major Depressive Disorder | Psychiatry | Jan 2027 |
| NCT05667142 | XEN1101 | Phase 3 | Primary Generalized Tonic-Clonic Seizures | Neurology | Apr 2027 |
| NCT07076407 | Azetukalner | Phase 3 | Major Depressive Disorder | Psychiatry | May 2027 |
| NCT05716100 | XEN1101 | Phase 3 | Focal Onset Seizures | Neurology | Jan 2028 |
| NCT07172516 | Azetukalner | Phase 3 | Bipolar Disorder | Psychiatry | Jun 2028 |
| NCT07217860 | Azetukalner | Phase 3 | Bipolar Depression | Psychiatry | Jun 2029 |
| NCT03796962 | XEN1101 | Phase 2 | Focal Epilepsy | Neurology | Oct 2030 |
Cash and short-term investments of $951m on 2026-09-30; operating cash outflow about $369m a year; runway about 31 months at that burn, to Apr 2029; 6 of 6 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 17 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Newron Pharmaceuticals Lipocine Actio Biosciences Rapport Therapeutics Sichuan Jishengtang Pharmaceutical
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.